TransMedics Provides Additional Information on the Impact of the Release of the Valuation Allowance on Deferred Tax Assets on Previously Reported Fourth Quarter Financial Results

Core Viewpoint - TransMedics Group, Inc. has released additional information regarding the impact of a valuation allowance on deferred tax assets, which significantly influenced its fourth quarter financial results for the year ended December 31, 2025 [1][2]. Financial Performance - In the fourth quarter of 2025, TransMedics released a $103.3 million U.S. tax valuation allowance, resulting in a net income tax benefit of $83.8 million [2]. - The annual effective tax rate for TransMedics in 2025 was (77.0)%, while it would have been 19.1% without the valuation allowance release, indicating a difference of 96.1 percentage points [3]. - The application of a 19.1% effective tax rate to fourth quarter income before income taxes of $21.6 million leads to an adjusted quarterly tax expense of $4.1 million [4]. - The reported fourth quarter net income was $105.4 million, translating to a net income per diluted share of $2.62. Adjusted net income, applying the 19.1% tax rate, would be $17.5 million, with a net income per diluted share of $0.47 [4][11]. Future Expectations - TransMedics anticipates recognizing a quarterly income tax provision that aligns more closely with U.S. statutory corporate income tax rates in future periods [5]. Company Overview - TransMedics is a leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation, aiming to improve organ quality and increase the utilization of donor organs for patients with end-stage heart, lung, and liver failure [6].